Eric Winquist

Summary

Affiliation: University of Western Ontario
Country: Canada

Publications

  1. ncbi request reprint Open clinical uro-oncology trials in Canada
    Eric Winquist
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 15:4034-42. 2008
  2. pmc Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group
    Eric Winquist
    Department of Medical Oncology, London Health Sciences Centre, London, Ontario, Canada
    BMC Cancer 6:112. 2006
  3. doi request reprint An evaluation framework for funding drugs for rare diseases
    Eric Winquist
    London Health Sciences Centre and Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
    Value Health 15:982-6. 2012
  4. ncbi request reprint Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study
    Eric Winquist
    London Health Sciences Centre, 790 Commissioners Road East, London, Ontario, Canada, N6A 4L6
    Invest New Drugs 24:159-67. 2006
  5. ncbi request reprint Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
    Christine Elser
    Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Hematology, Toronto, Ontario, Canada
    J Clin Oncol 25:3766-73. 2007
  6. ncbi request reprint Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
    Patricia A Tang
    Princess Margaret Phase II Consortium, Toronto, ON, Canada
    Invest New Drugs 26:257-64. 2008
  7. doi request reprint Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
    Fred Saad
    CRCUM Université de Montréal, Hamilton, Ontario, Canada
    Clin Cancer Res 17:5765-73. 2011
  8. doi request reprint Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents
    Gregory R Pond
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Ste 5 718, Toronto, Ontario, M5G 2M9, Canada
    J Clin Oncol 26:1324-30. 2008
  9. ncbi request reprint Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer
    Jonathan I Izawa
    Department of Surgery, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 13:48-53. 2006
  10. doi request reprint High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer
    Anthony C Nichols
    Victoria Hospital, London Health Science Centre, Department of Otolaryngology Head and Neck Surgery, Room B3 431A, 800 Commissioners Rd E, London, ON N6A 5W9, Canada
    JAMA Otolaryngol Head Neck Surg 139:617-22. 2013

Detail Information

Publications61

  1. ncbi request reprint Open clinical uro-oncology trials in Canada
    Eric Winquist
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 15:4034-42. 2008
  2. pmc Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group
    Eric Winquist
    Department of Medical Oncology, London Health Sciences Centre, London, Ontario, Canada
    BMC Cancer 6:112. 2006
    ..the impetus for a systematic review addressing the following question: which non-hormonal systemic therapies are most beneficial for the treatment of men with hormone-refractory prostate cancer (HRPC) and clinical evidence of metastases?..
  3. doi request reprint An evaluation framework for funding drugs for rare diseases
    Eric Winquist
    London Health Sciences Centre and Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
    Value Health 15:982-6. 2012
    ..The Ontario Public Drug Programs convened the Drugs for Rare Diseases Working Group to develop a policy for assessing these drugs...
  4. ncbi request reprint Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study
    Eric Winquist
    London Health Sciences Centre, 790 Commissioners Road East, London, Ontario, Canada, N6A 4L6
    Invest New Drugs 24:159-67. 2006
    ..Transaminitis was observed in patients with prior nephrectomy and appeared to be associated with altered drug exposure in these patients...
  5. ncbi request reprint Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
    Christine Elser
    Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Hematology, Toronto, Ontario, Canada
    J Clin Oncol 25:3766-73. 2007
    ..To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC)...
  6. ncbi request reprint Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
    Patricia A Tang
    Princess Margaret Phase II Consortium, Toronto, ON, Canada
    Invest New Drugs 26:257-64. 2008
    ..In addition, no pharmacodynamic changes were observed in peripheral blood mononuclear cells. We detected no antitumor activity of ispinesib in RMHNSC on this dosing schedule...
  7. doi request reprint Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
    Fred Saad
    CRCUM Université de Montréal, Hamilton, Ontario, Canada
    Clin Cancer Res 17:5765-73. 2011
    ..Patients and Methods: Men were randomized to receive either docetaxel + prednisone + custirsen (DPC) or mitoxantrone + prednisone + custirsen (MPC)...
  8. doi request reprint Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents
    Gregory R Pond
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Ste 5 718, Toronto, Ontario, M5G 2M9, Canada
    J Clin Oncol 26:1324-30. 2008
    ....
  9. ncbi request reprint Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer
    Jonathan I Izawa
    Department of Surgery, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 13:48-53. 2006
    ..Based on this data, we suggest optimal and feasible strategies for treating TCC in a resource-constrained environment...
  10. doi request reprint High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer
    Anthony C Nichols
    Victoria Hospital, London Health Science Centre, Department of Otolaryngology Head and Neck Surgery, Room B3 431A, 800 Commissioners Rd E, London, ON N6A 5W9, Canada
    JAMA Otolaryngol Head Neck Surg 139:617-22. 2013
    ..We set out to test this prediction in oropharyngeal patient samples from our institution...
  11. doi request reprint A phase I study of temsirolimus and metformin in advanced solid tumours
    Mary J Mackenzie
    London Health Sciences Centre, 790 Commissioners Rd East, London, ON, Canada N6A 4L6
    Invest New Drugs 30:647-52. 2012
    ..One patient with head and neck cancer experienced a partial response. Five patients had stable disease including a patient with melanoma who had stable disease for 22 months...
  12. doi request reprint A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184
    Helen J Mackay
    Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, Ontario M5G 2M9, Canada
    Gynecol Oncol 116:163-7. 2010
    ..This multi-centre phase II study was performed to evaluate the activity of sunitinib in women with locally advanced or metastatic cervical carcinoma who had received up to one prior line of chemotherapy for advanced disease...
  13. ncbi request reprint Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands
    Mark Agulnik
    Princess Margaret Hospital Phase II Consortium, Toronto, Ontario, Canada
    J Clin Oncol 25:3978-84. 2007
    ..This phase II study was conducted to determine the antitumor activity of lapatinib, a dual inhibitor of EGFR and erbB2 tyrosine kinase activity, in MSGTs...
  14. pmc Prognostic variables in adult Wilms tumour
    Jonathan I Izawa
    Department of Surgery, London Health Sciences Centre, London, Ont
    Can J Surg 51:252-6. 2008
    ..To identify outcomes and prognostic variables that predict survival outcomes in adult Wilms tumour patients...
  15. doi request reprint A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group
    Scott A Laurie
    Department of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, 501 Smyth Road, Ottawa ON K1H 8L6, Canada
    Cancer 116:362-8. 2010
    ..This phase 2 trial evaluated the combination of gemcitabine with cisplatin (carboplatin in those with protocol-defined contraindications to cisplatin)...
  16. ncbi request reprint Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer
    Kavitha Passaperuma
    Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
    Can J Urol 13:3009-15. 2006
    ..To explore this hypothesis further, we performed a retrospective analysis and report the efficacy, toxicity and pattern of failure with this approach...
  17. ncbi request reprint Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study
    Lillian L Siu
    Princess Margaret Hospital Phase II Consortium, Toronto, Toronto, Ontario, Canada
    J Clin Oncol 25:2178-83. 2007
    ....
  18. doi request reprint New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs
    Pieter H Anborgh
    London Regional Cancer Program, London, Ontario, Canada
    Clin Chem 55:895-903. 2009
    ..We compared both assays with 4 assays that recognize defined regions of OPN protein (dual polyclonal systems 5-1, 4-1, 4-3 and polyclonal-monoclonal system 1-3)...
  19. ncbi request reprint A Phase II study of oxaliplatin in urothelial cancer
    Eric Winquist
    Princess Margaret Hospital Phase II Consortium, London Regional Cancer Centre, London, Ontario, Canada
    Urol Oncol 23:150-4. 2005
    ..To assess the antitumor activity of oxaliplatin, a third generation platinum derivative with a 1,2-diaminocyclohexane (DACH) carrier ligand, in patients with metastatic transitional cell carcinoma of the bladder (TCC)...
  20. ncbi request reprint A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer
    Eric Winquist
    London Regional Cancer Centre, London, Ontario, Canada
    Urol Oncol 23:143-9. 2005
    ....
  21. doi request reprint Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
    Yoo Joung Ko
    Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
    Lancet Oncol 14:769-76. 2013
    ..In this phase 2 study, we assessed efficacy and tolerability of nanoparticle albumin-bound (nab) paclitaxel in platinum-refractory urothelial cancer...
  22. pmc Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR)--study protocol for a randomized phase II trial
    Anthony C Nichols
    Department of Otolaryngology Head and Neck Surgery, London Health Sciences Centre and Western University, London, Ontario, Canada
    BMC Cancer 13:133. 2013
    ..The goal of this randomized phase II study is to compare QOL, functional outcomes, toxicity profiles, and survival following primary RT (± chemotherapy) vs. TORS (± adjuvant [chemo] RT) in patients with OPSCC...
  23. doi request reprint Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial
    Ben Tran
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Int J Cancer 132:1547-55. 2013
    ..Additionally, actionable mutations identified in this study were relatively stable between archival and biopsy samples, implying that cancer mutations that are good predictors of drug response may remain constant across clinical stages...
  24. ncbi request reprint Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
    Mark Agulnik
    Princess Margaret Hospital Phase II Consortium, Toronto, Ontario, Canada
    J Clin Oncol 25:2184-90. 2007
    ..Additional biomarker studies with larger sample sizes are required to elucidate HNSCC patients who may benefit from this targeted therapy...
  25. ncbi request reprint Open clinical uro-oncology trials in Canada
    Eric Winquist
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 15:4284-90. 2008
  26. ncbi request reprint A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer
    Eric Winquist
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 11:2445-9. 2004
    ..To assess the efficacy and tolerability of a 3-week outpatient schedule of intravenous gemcitabine and cisplatin in patients with locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract (TCC)...
  27. ncbi request reprint Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)
    Jennifer J Knox
    Department of Medical Oncology, University Health Network OCI Princess Margaret Hospital, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Invest New Drugs 25:471-7. 2007
    ..The study closed, at the end of stage 1 as it did not meet the minimal efficacy criteria to proceed. Further evaluation of Triapine at this dose and schedule in patients with advanced kidney cancer is not recommended...
  28. ncbi request reprint Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis
    Eric Winquist
    London Health Sciences Centre, 790 Commissioners Rd E, London, Ontario, Canada N6A4L6
    Head Neck 29:38-46. 2007
    ..This systematic review evaluates the use of postoperative chemoradiotherapy for patients with advanced (stage III or IV) squamous cell carcinoma of the head and neck at a high risk of recurrence...
  29. ncbi request reprint The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials
    Scott Berry
    Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    Can J Urol 13:3180-8. 2006
    ..A systematic review of randomized controlled trials (RCTs) was performed to assess the benefits of bisphosphonate therapy in men with hormone-refractory prostate cancer (HRPC)...
  30. ncbi request reprint Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis
    Eric Winquist
    London Regional Cancer Centre, Ontario, Canada
    J Urol 171:561-9. 2004
    ..We determined whether neoadjuvant chemotherapy improved overall survival...
  31. doi request reprint Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system
    Anthony C Nichols
    Department of Otolaryngology Head and Neck Surgery, The University of Western Ontario, London, Ontario, Canada
    Head Neck 34:1440-4. 2012
    ..Early detection of circulating tumor cells (CTCs) offers the possibility of improved outcome for patients with head and neck squamous cell cancer (HNSCC)...
  32. ncbi request reprint Therapeutic targets for antimetastatic therapy
    Benjamin D Hedley
    Department of Medical Biophysics, University of Western Ontario, London Regional Cancer Program, London Health Sciences Centre, Ontario, N6A 4L6, Canada
    Expert Opin Ther Targets 8:527-36. 2004
    ..This review discusses potential biological targets, as defined by the steps in the metastatic process, for antimetastatic therapies and provides examples of clinical strategies for preventing or treating successful metastasis...
  33. ncbi request reprint Open clinical uro-oncology trials in Canada
    Mary J Mackenzie
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 15:4223-8. 2008
  34. ncbi request reprint Open clinical uro-oncology trials in Canada
    George Rodrigues
    London Health Sciences Center, London, Ontario, Canada
    Can J Urol 15:4130-7. 2008
  35. doi request reprint Recent advances in second-line treatment of castration-resistant prostate cancer
    Michael Ong
    Division of Medical Oncology, Department of Oncology, University of Western Ontario, London, Ontario, Canada
    Curr Opin Support Palliat Care 5:199-205. 2011
    ..This review addresses promising and practice-changing developments for the treatment of CRPC in the second-line setting...
  36. ncbi request reprint Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder
    Celina Ang
    Department of Surgery, University of Western Ontario, London, Ontario, Canada
    BJU Int 96:803-5. 2005
    ..To measure plasma levels of osteopontin in patients with transitional cell carcinoma (TCC) of the bladder, and to determine if osteopontin levels relate to disease stage...
  37. ncbi request reprint Open clinical uro-oncology trials in Canada
    Eric Winquist
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 14:3716-22. 2007
  38. ncbi request reprint Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination
    Carol A Townsley
    Princess Margaret Hospital Phase II Consortium, Ontario, Canada
    Clin Cancer Res 12:2141-9. 2006
    ..Adverse event data from clinical trials in the Princess Margaret Hospital Phase II Consortium database were analyzed to address this question...
  39. ncbi request reprint Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres
    D Scott Ernst
    London Regional Cancer Centre, London, Ontario, Canada
    Can J Urol 12:2575-80. 2005
    ..We evaluate the impact of surveillance programs on the outcome of men with clinical stage 1 NSGCT following orchidectomy...
  40. ncbi request reprint Open clinical uro-oncology trials in Canada
    George Rodrigues
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 14:3779-86. 2007
  41. ncbi request reprint Open clinical uro-oncology trials in Canada
    Mary MacKenzie
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 14:3662-7. 2007
  42. pmc Does HPV type affect outcome in oropharyngeal cancer?
    Anthony C Nichols
    Department of Otolaryngology, Head and Neck Surgery, The University of Western Ontario, Room B3 431A, 800 Commissioners Road East, London, N6A 5W9, Ontario, Canada
    J Otolaryngol Head Neck Surg 42:9. 2013
    ..The purpose of this study was to determine the rate of HPV-positive oropharyngeal cancer in Southwestern Ontario, Canada...
  43. ncbi request reprint Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)
    Georg A Bjarnason
    The Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    Invest New Drugs 23:51-6. 2005
    ..The secondary objective was to assess the toxicity profile...
  44. ncbi request reprint Open clinical uro-oncology trials in Canada
    Eric Winquist
    London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 15:3942-9. 2008
  45. ncbi request reprint Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose
    Mark Vincent
    London Regional Cancer Centre, 790 Commissioners Rd E, London, Ontario, N6A 4L6 Canada
    Clin Colorectal Cancer 2:111-8. 2002
    ..7). The predominant toxicities were stomatitis, diarrhea, and leukopenia. The standard Mayo Clinic regimen was associated with a higher level of dose-limiting toxicities than the accepted maximum of up to 33% for standard chemotherapy...
  46. ncbi request reprint Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review
    Katharine Shim
    Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada
    Drug Saf 31:359-71. 2008
    ..Routine screening for chemotherapy-associated osteonecrosis is not recommended; however, a high index of clinical suspicion in patients at risk may allow for early intervention and preservation of the joints...
  47. pmc Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer
    Malek B Hannouf
    Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
    PLoS ONE 7:e38557. 2012
    ....
  48. ncbi request reprint Hormone-refractory prostate cancer: a primer for the primary care physician
    Kylea Potvin
    Department of Oncology, University of Western Ontario and London Health Sciences Centre, 790 Commissioners Road East, London, Ontario, Canada
    Can J Urol 15:14-20; discussion 20. 2008
    ..To provide a current and evidence-based clinical review of practical value to primary care physicians encountering men with hormone-refractory prostate cancer (HRPC) in their practice...
  49. ncbi request reprint Chemotherapy for non-hormone refractory prostate cancer
    Eric Winquist
    Division of Medical Oncology, Department of Oncology, University of Western Ontario, London, Ontario, Canada
    Can J Urol 13:67-70. 2006
    ..These data have intensified interest in the use of chemotherapy for non-HRPC. Chemotherapy plus androgen deprivation therapy (ADT) is now under study in a number of RCTs in hormone-naïve patients...
  50. doi request reprint Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review
    Shashank Garg
    Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
    Support Care Cancer 18:667-77. 2010
    ..This systematic review addressed the question "Which interventions aimed at optimizing nutrition are of benefit to HNSCC patients receiving RT?"..
  51. ncbi request reprint Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline
    Roanne Segal
    Ottawa Regional Cancer Centre, Ontario, Canada
    Can J Urol 9:1625-33. 2002
    ..To examine the role of adjuvant chemotherapy in the treatment of patients with deep muscle-invasive transitional cell carcinoma (TCC) of the bladder who have undergone cystectomy...
  52. ncbi request reprint Perioperative chemotherapy for localized bladder cancer
    Eric Winquist
    University of Western Ontario and London Health Sciences Centre, London, Ontario, Canada
    Can J Urol 13:77-80. 2006
    ..Controversy and lack of awareness of these data have diminished their impact on daily practice, and they deserve further scrutiny...
  53. ncbi request reprint Malignant pheochromocytoma associated with germline mutation of the SDHB gene
    Zishan Allibhai
    Division of Radiation Oncology, London Regional Cancer Centre and University of Western Ontario, London, Ontario, Canada
    J Urol 172:1409-10. 2004
  54. ncbi request reprint A pilot study of regional participation in a videoconferenced multidisciplinary genitourinary tumor board
    Glenn Bauman
    Division of Radiation Oncology, Department of Oncology, London Regional Cancer Program London Health Sciences Centre, University of Western Ontario, 790 Commissioners Road East, London, Ontario N6A 4L6, Canada
    Can J Urol 12:2532-6. 2005
    ..Physician satisfaction with the rounds was high and participation beyond the pilot has continued. Scheduling in order to provide maximum access/participation has been the main logistical challenge with the rounds...
  55. doi request reprint Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer
    Kim N Chi
    Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro Oncology Group, Vancouver, British Columbia, Canada
    J Urol 180:565-70; discussion 570. 2008
    ..We assessed pathological outcomes as well as the feasibility of combined docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing prostatectomy...
  56. ncbi request reprint Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma
    Philip E Shaheen
    Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Invest New Drugs 23:577-81. 2005
    ..All 17 patients discontinued treatment due to disease progression or toxicity. Adverse events such as fatigue, nausea and diarrhea were common but generally mild. No evidence of anti-tumor activity of GD0039 was seen in this study...
  57. ncbi request reprint A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
    Gonzalo Gomez-Abuin
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Invest New Drugs 25:181-5. 2007
    ....
  58. ncbi request reprint Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
    Marshall R Posner
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 357:1705-15. 2007
    ....
  59. ncbi request reprint Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Eric Winquist
    J Natl Cancer Inst 96:1183; author reply 1183-1184. 2004
  60. ncbi request reprint Acute bilateral abducens paralysis due to oxaliplatin
    Eric Winquist
    J Natl Cancer Inst 95:488-9. 2003
  61. doi request reprint The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone
    Fred Saad
    University of Montreal Hospital Centre, Montreal, PQ, Canada
    BJU Int 102:551-5. 2008
    ....